Educational Webinar Series: Advanced Therapeutics in Paediatric Medicine
Register now for the first of a series of webinars that explores the way Advanced Therapeutics is driving clinicians and researchers to prepare for a new wave of therapies - revolutionising the future of paediatric health care.
We are in a new era of paediatric medicine. Therapy that targets the underlying genetic defect causing disease is now available for a small but increasing number of diseases. Join in as we hear from two world experts in gene therapy and Spinal Muscular Atrophy (SMA) and how an Australian-first SMA trial is leading to better outcomes for children with this devastating disease.
• Introduction to Advanced Therapeutics
• Gene Therapy 101
• Gene Therapy - The SMA story
• Q&A session – speakers, panel members and attendees
Date: Friday, 27 November 2020
Time: 2pm – 3pm (AEDT)
Professor Ian Alexander
Prof Alexander is the Head of the Gene Therapy Research Unit, a joint initiative of Children’s Medical Research Institute and The Children’s Hospital at Westmead. Within the Hospital he holds appointments as a senior staff specialist and as the Director of Laboratory Research. He is Professor in Paediatrics and Molecular Medicine in the Discipline of Child and Adolescent Health at the University of Sydney and an Honorary Consultant in Clinical Genetics at Westmead Hospital. His specific expertise and interests include virus-mediated gene transfer with a focus on target organs including the liver and bone marrow, both of which show great promise for the treatment of genetic disease in children.
Associate Professor Michelle Farrar
A/Prof Farrar is an Associate Professor in Paediatric Neurology at UNSW Sydney and specialist child neurologist at Sydney Children’s Hospital, leading the Neuromuscular clinical and research programs. She is a leading researcher in paediatric neuromuscular and rare neurogenetic disorders, successfully translating research to improve health practice and outcomes for patients, their families and the community. A/Prof Farrar’s team is focused on developing and translating innovative ways of providing the best possible care from the time of diagnosis, through treatment and beyond to people with neuromuscular, neurodevelopmental or rare neurogenetic diseases. The research program also integrates interdisciplinary genomics research, together with community and consumer involvement.